Danaher Corporation (DHR) reported earnings for the first quarter on 25th April. The report came in below guidance, resulting in the share price dropping.
Here are Biocompounding, we have been waiting for a pullback in Biotech picks & shovels plays to establish our position.
Following the report, we went through a valuation exercise to determine at what prices the company looks attractive and is a potential buy.
We first went through our valuation exercise on 27th Jan. Based on the reverse DCF seen below.
1) FCF - $7367Million
2) Growth rate of 7% cascading down to 3%
3) Discount rate of 8%